Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Recent & Breaking News (GREY:OBSEF)

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

GlobeNewswire February 26, 2018

ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018

GlobeNewswire February 23, 2018

ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018

GlobeNewswire February 7, 2018

Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons

GlobeNewswire February 1, 2018

ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018

GlobeNewswire January 5, 2018

ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017

GlobeNewswire December 7, 2017

ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

GlobeNewswire December 5, 2017

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire November 14, 2017

ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis

GlobeNewswire November 7, 2017

ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November

GlobeNewswire October 31, 2017

ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors

GlobeNewswire October 10, 2017

ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting

GlobeNewswire September 11, 2017

ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule

GlobeNewswire September 6, 2017

ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC

GlobeNewswire August 30, 2017

Mid-Morning Market Update: Markets Open Higher; Target Profit Tops Expectations

Benzinga.com  August 16, 2017

ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update

GlobeNewswire August 15, 2017

ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017

GlobeNewswire August 7, 2017

12 Biggest Mid-Day Gainers For Wednesday

Benzinga.com  July 5, 2017

9 Biggest Mid-Day Gainers For Friday

Benzinga.com  June 30, 2017

12 Biggest Mid-Day Gainers For Thursday

Benzinga.com  June 29, 2017